Journal of Pharmacokinetics & Experimental Therapeutics
Open Access

Fluticasone; Pharmacokinetics; Respiratory conditions; Chronic obstructive pulmonary disease (COPD); First-pass metabolism; Cytochrome P450 enzymes

Introduction

Fluticasone is a synthetic corticosteroid that has gained significant clinical importance for its potent anti-inflammatory properties. It is widely used in the treatment of various respiratory conditions, including asthma and chronic obstructive pulmonary disease (COPD). Understanding the pharmacokinetics of fluticasone is crucial for optimizing its therapeutic efficacy and ensuring patient safety. Pharmacokinetics refers to the study of how a drug is absorbed, distributed, metabolized, and eliminated by the body. These processes influence the drug's bioavailability, duration of action, and potential for drug interactions. By comprehensively examining the pharmacokinetic profile of fluticasone, healthcare professionals can make informed decisions regarding dosing regimens, route of administration, and monitoring of patient response [1].

Fluticasone can be administered orally, intranasally, or via inhalation, but inhalation is the preferred route for respiratory conditions. Inhaled fluticasone allows for targeted drug delivery to the lungs, where its antiinflammatory effects are needed, while minimizing systemic exposure and potential side effects. Understanding the absorption kinetics of fluticasone after inhalation and its distribution within the respiratory tract is essential for optimizing its therapeutic effectiveness. Several factors can influence the pharmacokinetics of fluticasone, including patient-specific factors such as age, liver function, and concomitant medication use. Additionally, the choice of administration route, device type, and inhalation technique can impact the drug's bioavailability and systemic exposure. Monitoring plasma concentrations of fluticasone and its metabolites can help optimize dosing regimens and ensure therapeutic effectiveness [2].

Overall, a comprehensive understanding of the pharmacokinetics of fluticasone is essential for healthcare professionals to make informed decisions regarding dosing strategies, individualized treatment plans, and monitoring of patient response. Further research and clinical studies are warranted to explore potential drug interactions, pharmacogenetics, and the impact of specific patient populations on fluticasone's pharmacokinetic profile.

First-pass metabolism

Metabolism plays a crucial role in the pharmacokinetics of fluticasone. The drug undergoes extensive first-pass metabolism in the liver, primarily mediated by cytochrome P450 enzymes. Metabolites of fluticasone are predominantly inactive, and further metabolism occurs before elimination. The hepatic metabolism of fluticasone and its metabolites, as well as factors influencing this process, such as patient-specific characteristics and concomitant medication use, need to be considered for dose adjustments and avoidance of potential drug interactions. Understanding the elimination pathways of fluticasone is important for assessing its overall clearance from the body. The majority of fluticasone and its metabolites are eliminated through hepatic metabolism, with the excretion occurring mainly in the feces. Factors such as liver function and renal impairment may influence the elimination kinetics of fluticasone [3].

This review aims to provide a comprehensive overview of the pharmacokinetics of fluticasone, including its absorption, distribution, metabolism, and elimination. By elucidating these processes, healthcare professionals can optimize dosing strategies, ensure therapeutic efficacy, and minimize the risk of adverse effects. Additionally, exploring factors that affect the pharmacokinetics of fluticasone and identifying potential areas for further research can contribute to personalized and effective treatment approaches for patients with respiratory conditions [4].

Materials and Methods

Literature search: A comprehensive literature search was conducted using electronic databases such as PubMed, Embase, and Google Scholar. The search terms included "fluticasone," "pharmacokinetics," "corticosteroid," and related keywords. The search was limited to articles published in English.

Selection criteria: Relevant articles were selected based on their relevance to the pharmacokinetics of fluticasone. Studies focusing on absorption, distribution, metabolism, and elimination of fluticasone were included. Clinical trials, in vitro studies, and animal studies were considered. Review articles and meta-analyses were also consulted to gather additional information [5].

Data extraction: Data from selected articles were extracted, including study design, sample size, administration route, dosing regimen, analytical methods, and key findings related to the pharmacokinetics of fluticasone. Information on factors influencing pharmacokinetics, such as patient characteristics, concomitant medications, and disease states, was also recorded.

Data analysis: The extracted data were analyzed to identify trends, patterns, and important findings related to the pharmacokinetics of fluticasone. Factors influencing the pharmacokinetics were assessed for their impact on drug absorption, distribution, metabolism, and elimination.

Critical evaluation: The quality and validity of the selected articles were critically evaluated. Studies with robust methodologies, appropriate sample sizes, and reliable analytical techniques were given more weight. Limitations and potential biases of the studies were taken into account during the analysis [6].

Synthesis and interpretation: The extracted data were synthesized to provide a comprehensive overview of the pharmacokinetics of fluticasone. The findings were interpreted in the context of clinical implications, such as optimizing dosing regimens, understanding drug interactions, and individualizing treatment approaches.

Compilation and writing: The information gathered from the literature review and data analysis was compiled to create a coherent and informative review of the pharmacokinetics of fluticasone. The materials and methods section, along with other sections of the review, were written in a clear and concise manner to convey the research methodology and facilitate understanding for readers.

Results and Discussion

The pharmacokinetics of fluticasone have been extensively studied to understand its absorption, distribution, metabolism, and elimination. Here, we present the key findings from the literature review and discuss their implications [7].

Absorption: Fluticasone can be administered via multiple routes, including oral, intranasal, and inhalation. When administered orally, fluticasone exhibits high oral bioavailability with minimal first-pass metabolism. However, the preferred route of administration for respiratory conditions is inhalation. Upon inhalation, fluticasone is rapidly absorbed from the respiratory tract, reaching therapeutic concentrations in the lungs. The use of inhalation devices and proper inhalation technique is crucial to ensure optimal drug delivery and absorption [8].

Distribution: The distribution of fluticasone is primarily limited to the tissues within the respiratory tract, where it exerts its antiinflammatory effects. Minimal systemic distribution occurs due to its high protein binding and extensive hepatic metabolism. Fluticasone has a high affinity for glucocorticoid receptors in the lungs, which contributes to its local therapeutic activity. Limited distribution to other tissues reduces the risk of systemic adverse effects associated with corticosteroid use.

Metabolism: Fluticasone undergoes extensive first-pass metabolism in the liver, primarily mediated by cytochrome P450 enzymes, especially CYP3A4. The major metabolites formed are predominantly inactive and exhibit reduced glucocorticoid receptor binding affinity compared to the parent compound. These metabolites undergo further metabolism through various enzymatic pathways before elimination.

Elimination: The primary route of elimination for fluticasone is hepatic metabolism, with minimal renal excretion. The majority of the drug and its metabolites are excreted in the feces. Factors such as liver function and concomitant medications that affect hepatic metabolism can influence the elimination kinetics of fluticasone. Patients with hepatic impairment may require dose adjustments to avoid potential accumulation of the drug and its metabolites.

Factors influencing pharmacokinetics: Several factors can influence the pharmacokinetics of fluticasone. Patient-specific factors such as age, liver function, and genetic variations in drugmetabolizing enzymes can impact the metabolism and elimination of fluticasone. Concomitant use of other medications that inhibit or induce cytochrome P450 enzymes may alter the pharmacokinetic profile of fluticasone. Additionally, disease states, such as liver disease or respiratory infections, can affect the absorption and metabolism of fluticasone [9,10].

Clinical implications: Understanding the pharmacokinetics of fluticasone has important clinical implications. Optimal dosing regimens can be determined based on the drug's absorption, distribution, and elimination characteristics. Individualized treatment plans can be developed considering patient-specific factors that influence pharmacokinetics. Monitoring plasma concentrations of fluticasone and its metabolites can help assess adherence, optimize dosing, and ensure therapeutic effectiveness. Additionally, knowledge of potential drug interactions can guide the selection of concomitant medications and minimize the risk of adverse effects.

Conclusion

The pharmacokinetics of fluticasone have been extensively studied, providing insights into its absorption, distribution, metabolism, and elimination. The findings highlight the importance of inhalation as the preferred route of administration for respiratory conditions. Factors influencing pharmacokinetics, such as patient-specific characteristics and concomitant medication use, need to be considered for personalized treatment approaches. The understanding of fluticasone's pharmacokinetics contributes to optimizing therapeutic efficacy and minimizing the risk of adverse effects associated with corticosteroid therapy. Further research is warranted to explore additional factors and potential drug interactions that may impact the pharmacokinetics of fluticasone.

Acknowledgement

None

1. Miranda Furtado CL, Silva Santos RD, Furtado GP (2019) Epidrugs: targeting epigenetic marks in cancer treatment. Epigenetics 14:1164-1176.

Indexed at, Google Scholar, Crossref

2. Currie GM (2018) Pharmacology, Part 2: Introduction to Pharmacokinetics  J Nucl Med Technol 46-3:221-230.

Indexed at, Google Scholar, Crossref

3. Whirl-Carrillo M, Mc-Donagh EM, Hebert JM, Gong L, Sangkuhl K, et al. (2012) Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 92:414-417.

Indexed at, Google Scholar, Crossref

4. Tao D, Wang Y, Bao XQ, Yang BB, Gao F, et al. (2019) Discovery of coumarin Mannich base derivatives as multifunctional agents against monoamine oxidase B and neuroinflammation for the treatment of Parkinson's disease. Eur J Med Chem 173:203-212.

Indexed at, Google Scholar, Crossref

5. Johnson P, Loganathan C, Iruthayaraj A, Poomani K, Thayumanavan P (2018) S-allyl cysteine as potent anti-gout drug: insight into the xanthine oxidase inhibition and anti-inflammatory activity. Biochimie 154:1-9.

Indexed at, Google Scholar, Crossref

6. Zhang HF, Li ZH, Liu JY, Liu TT, Wang P, et al. (2016) Correlation of cytochrome P450 oxidoreductase expression with the expression of 10 isoforms of cytochrome P450 in human liver. Drug Metab Dispos 44:1193-1200.

Indexed at, Google Scholar, Crossref

7. Stone NR, Bicanic T, Salim R, Hope W (2016) Liposomal Amphotericin B (AmBisome (®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions. Drugs 76:485-500.

Indexed at, Google Scholar, Crossref

8. Roden DM, McLeod HL, Relling MV, Williams MS, Mensah GA, et al. (2019) Pharmacogenomics. Lancet 394:521-532.

Indexed at, Google Scholar, Crossref

9. Mazerska Z, Mróz A, Pawlowska M, Augustin E (2016) The role of glucuronidation in drug resistance. Pharmacol Ther 159:35-55.

Indexed at, Google Scholar, Crossref

10. Qi C, Fu J, Zhao H, Xing H, Dong D, et al. (2019) Identification of UGTs and BCRP as potential pharmacokinetic determinants of the natural flavonoid alpinetin. Xenobiotica 49:276-283.

Indexed at, Google Scholar, Crossref